15-Deoxy-
12,14-prostaglandin J2
facilitates thyroglobulin production by cultured human
thyrocytes
Kikuo
Kasai1,
Nobuyuki
Banba1,
Akira
Hishinuma2,
Michiko
Matsumura1,
Hirofumi
Kakishita,
Mihoko
Matsumura1,
Satoshi
Motohashi1,
Noriyuki
Sato1, and
Yoshiyuki
Hattori1
1 Department of Endocrinology and Metabolism and
2 Department of Clinical Pathology, Dokkyo University School of
Medicine, Mibu, Tochigi 321-0293, Japan
 |
ABSTRACT |
A cyclopentenone-type prostaglandin,
15-deoxy-
12,14-prostaglandin J2
(15-d-PGJ2), has been shown to induce the cellular stress response and to be a ligand for the peroxisome proliferator-activated receptor (PPAR)-
. We studied its effect on the basal and thyrotropin (TSH)-induced production of thyroglobulin (TG) by human thyrocytes cultured in the presence of 10% FBS. In 15-d-PGJ2-treated
cells in which the agent itself did not stimulate cAMP production, both the basal production of TG and the response to TSH were facilitated, including the production of TG and cAMP, whereas such production was
decreased in untreated cells according to duration of culture. PGD2 and PGJ2, which are precursors to
15-d-PGJ2, exhibited an effect similar to
15-d-PGJ2. However, the antidiabetic thiazolidinediones known to be specific ligands for PPAR-
, and WY-14643, a specific PPAR-
ligand, lacked this effect. 15-d-PGJ2 and its
precursors, but not the thiazolidinediones, induced gene expression for
heme oxygenase-1 (HO-1), a stress-related protein, and strongly
inhibited interleukin-1 (IL-1)-induced nitric oxide (NO) production.
Cyclopentenone-type PGs have been recently shown to inhibit nuclear
factor-
B (NF-
B) activation via a direct and PPAR-independent
inhibition of inhibitor-
B kinase, suggesting that, in human
thyrocytes, such PGs may inhibit IL-1-induced NO production, possibly
via an inhibition of NF-
B activation. On the other hand, sodium
arsenite, a known activator of the stress response pathway, induced
HO-1 mRNA expression but lacked a promoting effect on TG production.
Thus 15-d-PGJ2 and its precursors appear to facilitate TG
production via a PPAR-independent mechanism and through a different
pathway from the cellular stress response that is available to
cyclopentenone-type PGs. Our findings reveal a novel role of these PGs
associated with thyrocyte differentiation.
thyrotropin; adenosine 3',5'-cyclic monophosphate; heme
oxygenase-1
 |
INTRODUCTION |
EICOSANOIDS,
which are oxygenated metabolites of arachidonic acid,
modulate cellular function during a variety of physiological and
pathological processes (30). Eicosanoids are divided into two groups, according to their mechanism of action: the conventional eicosanoids such as PGE2 and PGI2 and the
cyclopentenone-type prostaglandins (PGs). The conventional eicosanoids
act on cell surface receptors to exert their actions; the molecular
structure of their receptors has recently been revealed
(32). Cyclopentenone PGs such as
12-PGJ2,
15-deoxy-
12,14-PGJ2 (15-d-PGJ2),
and PGA2 lack cell surface receptors but are actively
transported into cells where they exert a wide variety of biological
actions, including the cessation of cell growth, antiviral activity,
and osteogenesis (9, 31). The actions of the
cyclopentenone PGs are attributed to the synthesis of the various
proteins. They induce, like the family of cytosolic heat shock proteins
(37, 44),
-glutamylcysteine synthetase
(38), collagen (51), gadd 153 (4), heme oxygenase (HO; see Ref. 25),
immunoglobulin-binding protein (Bip/GRP-78; see Ref. 36), p21WAP1/CiP (16), p53 (26), and
c-fos (14). Although their intracellular receptor had not been described, 15-d-PGJ2 was
recently shown to be a naturally occurring ligand for the
peroxisome proliferator-activated receptor (PPAR)-
(8, 23) and is a weak activator of PPAR-
(8, 23,
24). The PPARs belong to the nuclear receptor superfamily of
ligand-dependent transcription factors that activate the transcription of several genes. The differential activation of the PPAR-
and -
subtypes by several naturally occurring compounds such as fatty acids
and 15-d-PGJ2 and by such structurally distinct synthetic compounds such as fibrates and thiazolidinediones has been described and may explain their specific biological activities, including roles
in lipid and glucose metabolism and adipocyte differentiation (7,
8, 23, 24, 27, 46-48). In addition, an inhibitory role of
PPAR-
or PPAR-
activation has recently been reported in tissue
or in a cell-specific fashion by such ligands on the immune
system and/or inflammatory reaction (18, 40, 49). Despite
the widespread distribution of the receptors in various tissues, the
biological role of PPAR-
/
activation and that of its ligands
remains obscure.
In a functional rat thyroid epithelial cell line, the FRTL-5 cells,
either thyrotropin (TSH) or insulin stimulates the release of
arachidonic acid, the expression of cyclooxygenase, and the production
of PGD2 and PGE2 (50). In general,
thyrocytes cultured in the presence of high concentrations of serum
gradually lose their differentiated functions (2, 41). TSH
stimulates the differentiation of human thyrocytes and of FRTL-5 cells,
including the synthesis of thyroglobulin (TG), a precursor of thyroid
hormone, via a cAMP-dependent mechanism (5, 43). In the
present study, we observed the promoting effect of
15-d-PGJ2, a metabolite of PGD2, on the basal
and the TSH-stimulated production of TG in primary culture of human
thyrocytes in the presence of 10% fetal bovine serum (FBS). We then
examined whether the effect of 15-d-PGJ2 might be
attributed to the activation of PPARs or to some other pathway.
 |
MATERIALS AND METHODS |
Materials.
PGD2, PGJ2, 15-d-PGJ2, and WY-14643
were obtained from Cayman Chemical (Ann Arbor, MI). The antidiabetic
thiazolidinediones, troglitazone and pioglitazone, were kindly supplied
by Sankyo Pharmaceutical (Tokyo, Japan) and by Takeda Pharmaceutical
(Osaka, Japan), respectively. These agents were dissolved in DMSO. The final concentration of DMSO was
0.1%. Other chemicals were purchased from Sigma Chemical (St. Louis, MO).
Cell culture.
We obtained specimens of thyroid tissues from two patients with Graves
disease. Each specimen was digested with collagenase as described
elsewhere (20). The cells (open thyroid follicles) were
seeded on 48-well plates (0.2 ml/well) or 60-mm dishes (2 ml/dish) in
Ham's F-12 medium supplemented with 10% FBS and then were cultured
with 5% CO2 in a humidified atmosphere at 37°C. Cells
that reached confluence were used in these experiments. Contamination
by fibroblasts was found to be below 5%.
Assay of TG, cAMP, and nitrite in culture supernatant.
Assays of cAMP and TG in the culture supernatant were performed using
cAMP kits and TG kits, respectively, obtained from Yamasa (Chiba,
Japan) and Daiichi Radioisotope (Tokyo, Japan). Nitrite accumulation in
the culture medium was quantitated colorimetrically with Griess reagent
after a 48-h incubation, as reported elsewhere (20).
Cell respiration.
Cell respiration, an indicator of cell viability, was assessed by the
mitochondrion-dependent reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) to
formazan (29). To evaluate the cytotoxic effect of
15-d-PGJ2 and other agents, the cells were incubated at
37°C with MTT (0.4 mg/ml in fresh medium) for an additional 60 min after the final 48-h incubation. The culture medium was removed by
aspiration, and the cells were solubilized in DMSO. The extent of
reduction of MTT to formazan within the cells was quantified by the
measurement of absorbance at 550 nm. Formazan production was expressed
as a percentage of the value obtained from the control cells (basal condition).
Analysis of mRNA levels by RT-PCR.
RNA was extracted from thyrocytes in a 60-mM dish using a modified
guanidinium isothiocyanate method (Isogen, Takara, Japan). RT-PCR was
performed using the standard method. Briefly, the first-strand cDNA was
synthesized using random primers and Moloney murine leukemia virus RT
(Promega, Madison, WI), followed by PCR amplification using synthetic
gene primers specific for human TG (20), HO-1 (52) , inducible nitric oxide synthase (iNOS; see Ref.
20), PPAR-
(39), PPAR-
/
(39), PPAR-
(11), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as reported
previously (20). The following primers used were: TG
forward 21-mer, 5'-TGCCCTGGCAATGGAGACAAA-3'; TG reverse 21-mer,
5'-ACACGGGCTGACCTTTCTTAC-3'; HO-1 forward 21-mer, 5'-CAGGCAGAGAATGCTGAGTTC-3'; HO-1 reverse 18-mer,
5'-GCTTCACATAGCGCT GCA-3'; PPAR-
forward 21-mer,
5'-AGAACTTCAACATGAACAAGGTCA-3'; PPAR-
reverse 24-mer,
5'-GCCAGGACGATCTCCACAGCAAAT-3'; PPAR-
/
forward 21-mer,
5'-AGCAGCCTCTTCCTCAACGACCAG-3'; PPAR-
/
reverse 21-mer,
5'-GGTCTCGGTTTCGGTCTTCTTGAT-3'; PPAR-
forward 21-mer, 5'-GTTCATGCTTGTGAAGGATGC-3'; PPAR-
reverse 20-mer,
5'-ACTCTGGATTCAGCTGGTCG-3'; iNOS forward 21-mer, 5'-TGCCCTGGC
AATGGAGAGAAA-3'; iNOS reverse 21-mer, 5'-GAGCTGATGGAGTAGAAC CTG-3';
GAPDH forward 26-mer, 5'-TGAAGGTCGGAGTCAACGGATTTG GT-3'; GAPDH
reverse 24-mer, 5'-CATGTGGGCCATGAGGTCCACCAC-3'. PCR amplification
was performed for 30 cycles using a DNA PCR kit (Perkin-Elmer, Norwalk,
CT) as reported previously (20). PCR products were
electrophoresed on a 1.5% agarose gel that contained ethidium bromide
and were visualized by ultraviolet-induced fluorescence. All three
subtypes of PPAR were constitutively expressed in the primary culture
of human thyrocytes (Fig. 1). The size of
the amplified fragments was consistent with those predicted, being 524 bp for PPAR-
, 471 bp for PPAR-
/
, 250 bp for PPAR-
(Fig. 1),
613 bp for TG, 350 bp for HO-1, and 944 bp for iNOS (data not shown).

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of peroxisome proliferator-activated receptor
(PPAR) mRNAs in primary culture of human thyrocytes. Expression of
mRNAs for PPAR- , PPAR- / , and PPAR- was evaluated by RT-PCR
in thyrocytes cultured under basal conditions [Ham's F-12 medium
supplemented with 10% fetal bovine serum (FBS)]. Size markers are on
left. The sizes of the amplified fragments were consistent
with those predicted (524 bp for PPAR- , 471 bp for PPAR- / , 250 bp for PPAR- ).
|
|
Statistical analysis.
Values are expressed as means ± SD of three individual wells or a
mean of two individual dishes.
 |
RESULTS |
Changes in secretion of TG and cAMP and the gene expression for TG
and HO-1 in human thyrocytes over time.
We first studied the effects of 15-d-PGJ2, TSH, and their
combination on the changes in levels of TG and cAMP in the culture medium of human thyrocytes over time (Fig.
2, A and B).
Compared with basal conditions, the accumulation of TG was only
slightly higher at 24 h and was increased over twofold at 48 h in cells treated with 15-d-PGJ2 (10 µM) with no
apparent increase in the cAMP level. TSH (20 mU/ml) clearly stimulated
the accumulation of TG by more than twofold at 24 h and by more
than fivefold at 48 h, associated with a rapid, progressive
increment in the cAMP level. With their combined administration, the
increase in TG level was more prominent and appeared to be additive, or
even slightly greater, at 24 h and again at 48 h of
incubation. The accumulation of cAMP in the medium was not increased in
the early phase for up to 8 h but was increased in the late phase
of incubation (24-48 h) compared with that in the case of TSH
alone. As shown in Fig. 2C, either actinomycin D (Act D, 2.5 µg/ml) or cycloheximide (CHX, 10 µg/ml) completely inhibited
15-d-PGJ2-, TSH-, 15-d-PGJ2-, and
TSH-stimulated production of TG by the cells. We investigated by RT-PCR
the effects of 15-d-PGJ2, TSH, and their combination on the
gene expression for TG and for HO-1, a stress-related protein (Fig.
3A). Under basal conditions,
the level of TG mRNA declined according to the length of incubation
from 4 to 48 h. In the presence of 15-d-PGJ2, however,
the level of TG mRNA appeared to be slightly higher at 4 h than at
baseline and essentially remained at these levels throughout the
experiment. TSH markedly increased the level of TG mRNA. Their combined
administration also markedly increased such levels.
15-d-PGJ2 clearly increased the level of HO-1 mRNA as early
as 4 h; such levels were essentially maintained over 48 h.
However, TSH clearly did not induce the gene expression but rather
suppressed its basal expression. Even in the presence of TSH,
15-d-PGJ2 markedly increased the level of HO-1 mRNA at 4 h, which remained essentially unchanged at 48 h (Fig.
3A). The effects of Act D and CHX on the levels of mRNA for
TG and HO-1 at 24 h of incubation were studied further (Fig.
3B). The level of TG mRNA was almost completely suppressed
to the basal level by Act D and was also markedly suppressed by CHX
added to cells incubated with 15-d-PGJ2, TSH, or TSH plus
15-d-PGJ2. Act D completely inhibited the
15-d-PGJ2-induced expression of HO-1 mRNA, whereas CHX
greatly induced its expression.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Changes in levels of thyroglobulin (TG; A) and
cAMP (B) over time in the culture medium of thyrocytes and
effects of actinomycin D (Act D) and cycloheximide (CHX) on TG levels
(C). Human thyrocytes cultured in 60-mm dishes were
incubated in a medium containing 10% FBS alone (basal) or in a medium
supplemented with 15-deoxy- 12,14-prostaglandin
J2 (15-d-PGJ2, 10 µM), thyrotropin (TSH, 20 mU/ml), or 15-d-PGJ2 + TSH (10 µM + 20 mU/ml)
in the presence or absence of Act D (2.5 µg/ml) or CHX (10 µg/ml).
At the indicated times, the levels of TG and cAMP were measured in the
supernatant. Data represented are means of 2 dishes.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Changes in mRNA levels for TG and heme oxygenase-1 (HO-1)
in thyrocytes. A: time course changes in the levels of TG
mRNA and HO-1 mRNA in basal and 15-d-PGJ2 (10 µM)-, TSH
(20 mU/ml)-, or 15-d-PGJ2 + TSH (10 µM + 20 mU/ml)-stimulated conditions. B: expression of TG and HO-1
mRNAs in thyrocytes 24 h after incubation with
15-d-PGJ2 (10 µM), TSH (20 mU/ml), or
15-d-PGJ2 + TSH (10 µM + 20 mU/ml) in the
presence or absence of Act D (2.5 µg/ml) and CHX (10 µg/ml). Levels
of mRNA for TG and HO-1 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as a reference were evaluated by RT-PCR.
|
|
Effects of various doses of 15-d-PGJ2 on basal and TSH-
or dibutyryl cAMP-stimulated levels of TG.
The amount of TG secreted by the cells during an incubation for 48 h was slightly higher in the presence of 1 µM 15-d-PGJ2 and was over three times higher with 10 µM 15-d-PGJ2 than
in its absence. However, the level of TG tendered to decrease in the presence of 30 µM 15-d-PGJ2 (Fig.
4A). This dose was cytotoxic as assessed by the MTT assay (Fig. 4C). The amount of cAMP that accumulated under these conditions tended to decrease with the addition
of 10 µM or more 15-d-PGJ2 (Fig. 4B). TSH (20 mU/ml) used alone strongly stimulated TG accumulation by about fivefold and was associated with a profound increase in the level of cAMP. This
TSH-stimulated accumulation of TG was further promoted and was
associated with an increase in cAMP production by 15-d-PGJ2 administered at doses ranging from 1 to 10 µM. Dibutyryl cAMP (0.5 mM) also stimulated TG accumulation. Such stimulation appeared to be
slightly increased by the coadministration of 1-10 µM
15-d-PGJ2.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of various doses of 15-d-PGJ2 on
basal, dibutyryl cAMP (DBC), and TSH-induced levels of TG
(A) and cAMP (B) in the culture medium of
thyrocytes. Human thyrocytes cultured in 48-well plates were incubated
for 48 h with graded doses of 15-d-PGJ2 in the
presence or absence of DBC (0.5 mM) or TSH (20 mU/ml). C:
after 48 h of incubation, cell respiration was measured by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
assay. Data represented are means ± SD of 3 wells.
|
|
Comparable levels of TG and cAMP under basal and TSH-stimulated
conditions in untreated thyrocytes vs. those treated with
15-d-PGJ2.
We next compared the levels of TG and cAMP under basal and
TSH-stimulated conditions during the final 48 h of incubation in thyrocytes treated with or without 5 µM 15-d-PGJ2 for
48-144 h. As shown in Fig. 5,
A and B, both the basal and TSH (20 mU/ml)-stimulated levels of TG gradually decreased according to
duration of culture in the untreated (control) thyrocytes. The
TSH-stimulated accumulation of cAMP decreased in a similar manner in
such cells. Both the basal TG and TSH-stimulated TG and cAMP levels
were clearly higher in the cells treated with 15-d-PGJ2
compared with untreated cells. However, the basal accumulation of cAMP
showed no significant change in the cells untreated or treated with
15-d-PGJ2 throughout the experiment; all of the values were
below 1 pmol/ml.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 5.
Comparable levels of TG (A) and cAMP (B) and
the levels of mRNA for TG and HO-1 (C) under basal and
TSH-stimulated conditions in untreated (control) vs. treated thyrocytes
with 15-d-PGJ2 for various durations. Human thyrocytes
cultured in 60-mm dishes were cultured in the absence and presence of 5 µM 15-d-PGJ2 for various periods of time (48, 96, or
144 h), including a final 48 h of incubation. The basal and
TSH (20 mU/ml)-stimulated levels of TG and cAMP during the final
48 h of incubation were measured. Data represent means of 2 dishes. The levels of mRNAs for TG and HO-1 and GAPDH as reference were
evaluated by RT-PCR at the indicated times.
|
|
The basal level of TG mRNA showed a gradual decrease in untreated cells
in accordance with the duration of culture, whereas the response to TSH
regarding the expression of TG mRNA remained relatively unchanged
throughout the experiment (Fig. 5C). In the 15-d-PGJ2-treated cells, both the expression of TG mRNA in
response to TSH and the basal level of TG mRNA were maintained.
Effects of pretreatment, treatment, and continuous treatment with
15-d-PGJ2 on the accumulation of TG and cAMP under basal
and TSH-stimulated conditions.
We evaluated the effects of the pretreatment, treatment, and continuous
treatment (pretreatment and treatment) of the cells with 5 µM
15-d-PGJ2 on the basal and the TSH-stimulated TG and cAMP
accumulation during the final 48 h of incubation (Fig.
6, A and B). The
administration of 5 µM 15-d-PGJ2 during the final 48 h of incubation promoted both the basal and TSH (0.02-20
mU/ml)-induced production of TG compared with the control condition.
Cells pretreated for 48 h with 5 µM 15-d-PGJ2
produced greater amounts of TG in the basal and in the TSH-stimulated
conditions during the final 48 h of incubation compared with the
untreated cells or cells treated only during the final incubation.
Continuous treatment with 5 µM 15-d-PGJ2 showed the
highest level of both the basal and TSH-induced production of TG (Fig.
6A). The basal accumulation of cAMP was zero and was not
influenced by pretreatment, treatment, or continuous treatment with 5 µM 15-d-PGJ2. However, the TSH (0.02-20
mU/ml)-stimulated accumulation of cAMP was clearly enhanced by
treatment, pretreatment, and continuous treatment, in that order (Fig.
6B).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of pretreatment, treatment, and continuous (pretreatment
and treatment) treatment with 15-d-PGJ2 on basal and
TSH-induced levels of TG (A) and cAMP (B) in the
final incubation medium of the thyrocytes. Human thyrocytes in 48-well
plates were first preincubated in the presence or absence of 5 µM
15-d-PGJ2 for 48 h. The medium was then aspirated and
washed one time with the fresh medium and was finally incubated with
various doses of TSH (0-20 mU/ml) in the presence or absence of 5 µM 15-d-PGJ2 for 48 h. The amounts of TG and cAMP in
the final incubation medium were measured. Data represented are
means ± SD of 3 wells.
|
|
Effects of treatment or pretreatment of thyrocytes with PGs and
synthetic ligands of PPARs on TG or cAMP accumulation and expression of
HO-1 mRNA.
The effects of administering various doses of such agents as
15-d-PGJ2, its precursor PGs (PGD2 or
PGJ2), the synthetic PPAR-
ligands troglitazone and
pioglitazone, and PPAR-
ligand (WY-14643) on the basal and
TSH-stimulated accumulation of TG were examined during 48 h of
incubation. Basal TG production was increased by 10 µM
15-d-PGJ2, PGD2, or PGJ2 compared
with that by untreated cells. The TSH (20 mU/ml)-induced accumulation
of TG was also clearly increased by the cells treated with such PGs
dose dependently, from 1 to 10 µM (Fig.
7A). However, neither one of
the antidiabetic thiazolidinediones (0.1-10 µM) nor WY-14643
(0.1-50 µM) showed such an effect on the basal or TSH-induced
production of TG (Fig. 7B).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of various PGs and ligands for PPAR- / on basal and
TSH-induced TG levels during incubation of thyrocytes for 48 h.
Human thyrocytes in 48-well plates were incubated for 48 h with
various doses of PGD2, PGJ2, or
15-d-PGJ2 (0.1-10 µM; A) and with specific ligands
for PPAR- (troglitazone or pioglitazone: 0.1-10 µM) or for
PPAR- (WY-14643: 0.1-50 µM; B) in the presence or
absence of TSH (20 mU/ml). The amounts of TG accumulated in the medium
were measured. Data represented are a means ± SD of 3 wells.
|
|
We next examined the effects of 48 h of pretreatment with such
agents on the basal or TSH-stimulated accumulation of TG and cAMP
during the next 48 h of incubation (Fig.
8, A and B). During preincubation, the accumulation of TG by the cells was higher in the
presence of PGD2, PGJ2, or
15-d-PGJ2 (each 5 µM) than in the untreated cells. The
accumulation of basal TG clearly declined in the untreated cells during
the final incubation period compared with preincubation. In contrast,
the basal level of TG in the final incubation by cells pretreated with
each PG was similar to that observed during preincubation with no
apparent change in cAMP accumulation. The TSH-stimulated accumulation
of TG and cAMP during the final 48 h of incubation was clearly
higher in the cells pretreated with PGD2, PGJ2,
or 15-d-PGJ2 than in the untreated cells (Fig. 8,
A and B). Neither troglitazone nor pioglitazone (each 5 µM) or WY-14643 (50 µM) exhibited any effect on either parameter (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 8.
Effects of pretreatment of thyrocytes with PGs on basal
and TSH-induced TG (A) and cAMP (B) levels during
final incubation of thyrocytes. Human thyrocytes in 48-well plates were
preincubated for 48 h with PGD2, PGJ2, or
15-d-PGJ2 (each 5 µM). The medium was then aspirated and
replaced with fresh medium that contained various doses of TSH
(0-20 mU/ml) and was further incubated for 48 h. The
respective amounts of TG and cAMP in the preincubation or final
incubation medium were measured. Data represent means ± SD of 3 wells.
|
|
In the absence of TSH, the induction of gene expression of HO-1 in the
cells treated with 10 µM 15-d-PGJ2, PGD2, or
PGJ2 was observed at 4 and 24 h after their addition,
whereas neither troglitazone nor pioglitazone (10 µM) or WY-I4632 (50 µM) showed such an effect (Fig. 9).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 9.
Effects of various PGs and ligands for PPAR- / on
the expression of HO-1. Human thyrocytes in 60-mm dishes were incubated
for 4 or 24 h with 15-d-PGJ2, PGJ2, or
PGD2 (each 10 µM) and with specific ligands for PPAR-
[troglitazone (Tro) or pioglitazone (Pio): each 10 µM] or for
PPAR- [WY-14643 (Wy): 50 µM] in the absence of TSH. Levels of
mRNA for HO-1 and GAPDH as a reference were evaluated by RT-PCR.
|
|
Effects of 15-d-PGJ2 and thiazolidinediones on
inducible nitric oxide production.
The effects of administering 15-d-PGJ2, PGD2,
and the synthetic PPAR-
ligands troglitazone and pioglitazone on
IL-1-induced accumulation of nitric oxide (NO) measured as nitrite were
examined during 48 h of incubation. IL-1-induced NO production was
dose dependently inhibited by 15-d-PGJ2 and
PGD2, with the doses ranging from 5 to 20 µM.
Pioglitazone did not affect but troglitazone inversely stimulated NO
production with the doses from 5 to 20 µM (Fig.
10, A and B). The
IL-1-induced expression of iNOS mRNA was suppressed in
15-d-PGJ2 (10 µM)-treated cells but was inversely increased in troglitazone (10 µM)-treated cells at 24 h. In the pioglitazone-treated cells, its level seemed to be unaffected to any
major extent (Fig. 10C).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 10.
Changes in nitric oxide (NO) production (A and
B) and in the levels of inducible nitric oxide synthase
(iNOS) mRNA (C) in interleukin (IL)-1-activated thyrocytes
treated with and without 15-d-PGJ2, PGD2,
troglitazone, or pioglitazone. Human thyrocytes cultured in 48-well
plate were incubated for 48 h with graded doses of IL-1 (0-10
ng/ml) in the presence or absence of 10 µM of each agent and with 10 ng/ml IL-1 in the presence or absence of graded doses of each agent
(0-20 µM). Nitrite accumulation in the culture medium was
measured. Data represent means ± SD of 3 wells. The cells
cultured in 60-mm dishes were activated with IL-1 (10 ng/ml) in the
presence or absence of 10 µM of each agent. The levels of iNOS mRNA
and GAPDH as reference were evaluated by RT-PCR at the indicated
times.
|
|
Effects of sodium arsenite on basal and TSH-stimulated TG
production and HO-1 and TG mRNA expression.
After pretreatment of the cells with or without 50 µM sodium arsenite
for 1 h, basal and TSH-stimulated TG accumulation in the fresh
culture medium was compared with that in control and 15-d-PGJ2 (10 µM)-treated cells during the next 48 h
of incubation. Sodium arsenite pretreatment did not increase TG
production, but 15-d-PGJ2 treatment facilitated its
production (Fig. 11A).
Pretreatment with sodium arsenite strongly induced HO-1 mRNA expression
in the cells over 4-48 h, whereas TG mRNA expression in response to TSH was similar to that in control cells (Fig. 11B).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 11.
Effect of pretreatment with sodium arsenite on basal and
TSH-stimulated TG production (A) and the expression of mRNA
for TG and HO-1 over time (B). Human thyrocytes were
pretreated with or without 50 µM sodium arsenite for 1 h. Basal
and TSH (0.1-10 mU/ml)-stimulated TG production for the next
48 h in the fresh medium by arsenite-pretreated thyrocytes was
compared with that by the cells incubated in the absence (control) or
presence of 10 µM 15-d-PGJ2. Data represent means ± SD of 3 wells. The cells cultured in 60-mm dishes were pretreated with
50 µM sodium arsenite for 1 h. The medium was replaced with the
fresh medium, and the cells were cultured further for 48 h in the
presence of TSH (10 mU/ml). The levels of TG and HO-1 mRNAs and GAPDH
as reference were evaluated by RT-PCR at the indicated times.
|
|
 |
DISCUSSION |
When human thyrocytes were cultured with 10% FBS, both the basal
production of TG and the response to TSH, including the production of
TG and cAMP production, showed a gradual decrease in accordance with
duration of culture. These results are compatible with previous reports
showing that thyrocytes cultured in the presence of high concentrations
of serum gradually lose the differentiation function (2,
41). Although 15-d-PGJ2 alone failed to stimulate
cAMP production, both the basal production of TG and the response to TSH were facilitated in the thyrocytes treated with
15-d-PGJ2. PGD2 and PGJ2 (precursor
PGs for 15-d-PGJ2) had an effect similar to
15-d-PGJ2. Because PGD2 rapidly undergoes
dehydration in aqueous media to form PGJ2 and is converted
in the presence of serum or albumin to
12-PGJ2 and 15-d-PGJ2 (1,
15, 22, 28), the effects of PGD2 and
PGJ2 appear to be expressed via this cascade of the
PGJ2 series. Furthermore, the promoting effect of these PGs
on both the basal production of TG and the response to TSH, including
the production of TG and cAMP, was more clearly observed in the
continuously treated (pretreated and treated) and pretreated cells than
in those treated only in the final incubation (Figs. 6 and 8). Thus the
promoting effect of 15-d-PGJ2 or its precursor PGs on the thyrocytes may be attributed to the suppression of dedifferentiation and/or to the facilitation of differentiation via cAMP-independent and
TSH- and cAMP-dependent mechanisms.
Various chemicals and conditions can trigger a protective homeostatic
mechanism (stress response) in eukaryotic cells. Because it has been
reported that the cyclopentenone PGs also activate the stress response
pathway, resulting in the induction of various stress-related proteins,
including HO-1 and members of molecular chaperones in the cytosol and
endoplasmic reticulum (4, 25, 36-38, 44, 51), we
investigated whether 15-d-PGJ2, PGJ2, and PGD2 might induce the stress response in human thyrocytes
by assessing the gene expression of HO-1 (25). Both
15-d-PGJ2 and PGJ2 markedly and
PGD2 less potently induced gene expression for HO-1,
indicating that these PGs may in fact activate the stress response
pathway in human thyrocytes. 15-d-PGJ2 was recently shown
to be a ligand for PPAR-
and was also shown to be a weak activator
of PPAR-
(8, 23, 24). To clarify whether the activation
of PPARs by 15-d-PGJ2 may contribute to the promotion of
basal TG production and the response to TSH, we further investigated
the effects on such parameters of activators of PPAR-
and -
. We
first confirmed that the mRNAs for PPAR subtypes (
,
/
, and
) were all expressed in human thyrocytes. In contrast to
15-d-PGJ2 and its precursor PGs, the synthetic activators
of PPAR-
, troglitazone, and pioglitazone, and a synthetic activator
of PPAR-
, WY-14643, failed to promote the production of TG.
15-d-PGJ2 and its precursors have initially been shown to
inhibit the production of proinflammatory cytokines and inducible NO in
activated monocytes by a mechanism suggested to PPAR-
activation
that interferes with nuclear factor (NF)-
B transcriptional activity
(18, 40). However, it has recently been shown that a
cyclopentenone type of PGs inhibits NF-
B activation via direct and
PPAR-
-independent inhibition of inhibitor-
B kinase (42). Thus we next examined and clarified that
interleukin-1 (IL-1)-induced NO production was strongly inhibited by
15-d-PGJ2 and PGD2 but not by the
thiazolidinediones. Troglitazone, but not pioglitazone, inversely
stimulated IL-1-induced NO production; these results are compatible
with our previous report in rat vascular smooth muscle cells
(12). Although IL-1 was shown to inhibit TG mRNA and
protein production in human thyrocytes (54), we have
observed in a preliminary study that IL-1-induced inhibition of TG
production can be restored partially by the coadministration of
15-d-PGJ2 but not by the thiazolidinediones in the cells.
These results clearly indicated that 15-d-PGJ2 and its
precursor PGs have PPAR-independent effects on thyrocyte functions. We
thus conclude in human thyrocytes that the promoting effect of
15-d-PGJ2 and of its precursor PGs on basal TG production
and the response to TSH is independent of PPAR activation. It is
compatible with a recent report showing that 15-d-PGJ2 and
PGJ2 promote the differentiation (i.e., neurite outgrowth)
by nerve growth factor in PC-12 cells via a mechanism that is
independent of PPAR-
activation (45). Accordingly, it
is suggested that the promoting effect by such PGs on TG production in
human thyrocytes might be associated with an inhibition of NF-
B
activation, an activation of the stress response pathway, or an unknown
mechanism. We finally studied the effect of sodium arsenite, a
prototype activator of the stress response pathway (1, 3,
17), on HO-1 mRNA expression and TG production in human
thyrocytes. Pretreatment of the cells with sodium arsenite strongly
induced HO-1 mRNA expression but lacked a promoting effect on basal and
TSH-stimulated TG production. Accordingly, it seems unlikely that an
activation of the stress response pathway may be directly related with
such promoting effect on TG production.
Arachidonic acid metabolism is highly increased in several pathological
conditions such as infection and inflammation (13, 33),
and local PG concentrations in the micromolar range have been detected
at sites of acute inflammation (35). Elevated cyclopentenone-type PGs have been detected in the late phase of inflammation and are associated with resolution of inflammation (10, 18, 40). Subacute thyroiditis possibly caused by
certain viral infections and silent thyroiditis caused by an acute
exacerbation of the autoimmune process related with autoimmune
thyroiditis are called destructive thyroiditis, which generally
exhibits reversible thyroid dysfunction associated with destruction and
subsequent regeneration of thyroid follicles (34). In both
destructive thyroiditis and chronic autoimmune thyroiditis,
monocytes/macrophages, which are known to produce PGD2
(10, 18, 40) and lymphocytes, are prominent in the
infiltrates of the thyroid (34, 53). The local expression
in autoimmune thyroiditis of various cytokines, including IL-1 and
tumor necrosis factor-
, has been reported, and these cytokines are
produced by infiltrated inflammatory cells and/or thyrocytes themselves
(53). Although it has not yet been reported whether human
thyrocytes can produce PGD2, TSH and insulin have been
shown to stimulate PGD2 and PGE2 production in
FRTL-5 cells (50). Furthermore, we already reported that
IL-1 stimulates PGE2 production by porcine thyroid cells
(21) and monocyte chemoattractant protein-1 by human
thyrocytes (19). Thus PGD2 produced locally in
the thyroid might have a role on the resolution of inflammation and the
functional restoration of human thyrocytes through the cascade of
PGJ2 series.
The present findings indicate that a cyclopentenone-type PG,
15-d-PGJ2, and its precursor PGs may stimulate TG
production by themselves with no increase in cAMP production and
further potentiate the TSH-stimulated production of TG accompanied by an increase in cAMP production in human thyrocytes that were cultured in a high serum concentration. In conclusion, such promoting effect by
15-d-PGJ2 and its precursor PGs in human thyrocytes is
independent of the activation of PPAR-
or -
and also is probably
independent of an activation of the stress response pathway. Because
the mechanism of dedifferentiation of thyrocytes cultured in the
presence of high serum concentrations is unknown at present, the exact
mechanism of the promoting effect by 15-d-PGJ2 and its
precursor PGs on TG production remains to be elucidated.
 |
ACKNOWLEDGEMENTS |
This work was supported in part by a grant from the Japan Private
School Promotion Foundation.
 |
FOOTNOTES |
Address for reprint requests and other correspondence: K. Kasai, Dept. of Endocrinology and Metabolism, Dokkyo Univ.
School of Medicine, Mibu, Tochigi 321-0293, Japan (E-mail:
kkasai{at}dokkyomed.ac.jp).
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 28 September 1999; accepted in final form 26 May 2000.
 |
REFERENCES |
1.
Albert, KK,
Whitmarsh AJ,
Davis RJ,
and
Bonkovsky HL.
Mechanism of sodium arsenite-mediated induction of hemeoxygenase-1 in hepatoma cells: role of mitogen-activated protein kinases.
J Biol Chem
273:
8922-8931,
1998[Abstract/Free Full Text].
2.
Brabant, G,
Hoang-Vu C,
Behrends J,
Cetin Y,
Potter E,
Dumondt JE,
and
Maenhant C.
Regulation of the cell-cell adhesion protein, E-cadherin, in dog and human thyrocytes in vitro.
Endocrinology
136:
3113-3119,
1995[Abstract].
3.
Brostrom, CO,
Prostko CR,
Kaufman RJ,
and
Brostrom MA.
Inhibition of translational initiation by activators of the glucose-regulated stress protein and heat shock protein stress response systems. Role of the interferon-inducible double-stranded RNA-activated eukaryotic initiation factor 2alpha kinase.
J Biol Chem
271:
24995-5002,
1996[Abstract/Free Full Text].
4.
Choi, AM,
Fargnoli J,
Carlson SG,
and
Holbrook NJ.
Cell growth inhibition by prostaglandin A2 results in elevated expression of gadd153 mRNA.
Exp Cell Res
199:
85-89,
1992[ISI][Medline].
5.
Collison, KS,
Banga JP,
Barnett PS,
Kung AW,
and
McGregor AM.
Activation of the thyroid peroxidase gene in human thyroid cells: effect of thyrotropin, forskolin and phorbol ester.
J Mol Endocrinol
3:
1-5,
1989[Abstract].
6.
Fitzpatrick, FA,
and
Wynalda MA.
Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro.
J Biol Chem
258:
11713-11718,
1983[Abstract/Free Full Text].
7.
Forman, BM,
Chen J,
and
Evans RM.
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.
Proc Natl Acad Sci USA
94:
4312-4317,
1997[Abstract/Free Full Text].
8.
Forman, BM,
Tontonoz P,
Chen J,
Brun RP,
Spiegelman BM,
and
Evans RM.
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR
.
Cell
83:
803-812,
1995[ISI][Medline].
9.
Fukushima, M.
Biological activities and mechanisms of action of PGJ2 and related compounds: an update.
Prostaglandins Leukot Essent Fatty Acids
47:
1-12,
1992[ISI][Medline].
10.
Gilroy, DW,
Colville-Nash PR,
Willis D,
Chivers J,
Paul-Clark MJ,
and
Willoughby DA.
Inducible cyclooxygenase may have anti-inflammatory properties.
Nat Med
5:
698-701,
1999[ISI][Medline].
11.
Guan, Y,
Zhang Y,
Davis L,
and
Breyer MD.
Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans.
Am J Physiol Renal Physiol
273:
F1013-F1022,
1997[Abstract/Free Full Text].
12.
Hattori, Y,
Hattori S,
and
Kasai K.
Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells.
Hypertension
33:
943-948,
1999[Abstract/Free Full Text].
13.
Herschman, HR,
Reddy ST,
and
Xie W.
Function and regulation of prostaglandin synthase-2.
Adv Exp Med Biol
407:
61-66,
1997[ISI][Medline].
14.
Higashiyama, K,
Niiya K,
Ozawa T,
Hayakawa Y,
Fujimaki M,
and
Sakuragawa N.
Induction of c-fos protooncogene transcription and apoptosis by delta 12-prostaglandin J2 in human Pl-21 myeloid leukemia and RC-K8 pre-B lymphoma cells.
Prostaglandins
52:
143-156,
1996[Medline].
15.
Hirata, Y,
Hayashi H,
Ito S,
Kikawa Y,
Ishibashi M,
Sudo M,
Miyazaki H,
Fukushima M,
Narumiya S,
and
Hayaishi O.
Occurrence of 9-deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2 in human urine.
J Biol Chem
263:
16619-16625,
1988[Abstract/Free Full Text].
16.
Ishikawa, T,
Akimaru K,
Nakanishi M,
Tomokiyo K,
Furuta K,
Suzuki M,
and
Noyori R.
Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GSXpump).
Biochem J
336:
569-576,
1998[ISI][Medline].
17.
Ito, H,
Okamoto K,
and
Kato K.
Prostaglandins stimulate the stress-induced synthesis of hsp27 and alpha B crystallin.
J Cell Physiol
170:
255-262,
1997[ISI][Medline].
18.
Jiang, C,
Ting AT,
and
Seed B.
PPAR-
agonists inhibit production of monocyte inflammatory cytokines.
Nature
391:
82-86,
1998[ISI][Medline].
19.
Kasai, K,
Banba N,
Motohashi S,
Hattori Y,
Manaka K,
and
Shimoda SI.
Expression of monocyte chemoattractant protein-1 mRNA and protein in cultured human thyrocytes.
FEBS Lett
394:
137-140,
1996[ISI][Medline].
20.
Kasai, K,
Hattori Y,
Nakanishi N,
Manaka K,
Banba N,
Motohashi S,
and
Shimoda S.
Regulation of inducible nitric oxide production by cytokines in human thyrocytes in culture.
Endocrinology
136:
4261-4270,
1995[Abstract].
21.
Kasai, K,
Hiraiwa M,
Emoto T,
Kuroda H,
Hattori Y,
Mochizuki Y,
Nakamura T,
and
Shimoda S.
Presence of high affinity receptor for interleukin-1 (IL-1) on cultured porcine thyroid cells.
Horm Metab Res
22:
75-79,
1990[ISI][Medline].
22.
Kikawa, Y,
Narumiya S,
Fukushima M,
Wakatsuka H,
and
Hayaishi O.
9-Deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma.
Proc Natl Acad Sci USA
81:
1317-1321,
1984[Abstract].
23.
Kliewer, SA,
Lenhard JM,
Willson TM,
Patel I,
Morris DC,
and
Lehmann JM.
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor
and promotes adipocyte differentiation.
Cell
83:
813-819,
1995[ISI][Medline].
24.
Kliewer, SA,
Sundseth SS,
Jones SA,
Brown PJ,
Wisely GB,
Koble CS,
Devchand P,
Wahli W,
Willson TM,
Lenhard JM,
and
Lehmann JM.
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors
and
.
Proc Natl Acad Sci USA
94:
4318-4323,
1997[Abstract/Free Full Text].
25.
Koizumi, T,
Negishi M,
and
Ichikawa A.
Induction of heme oxygenase by delta 12-prostaglandin J2 in porcine aortic endothelial cells.
Prostaglandins
43:
121-131,
1992[Medline].
26.
Lee, JH,
Kim HS,
Jeong SY,
and
Kim IK.
Induction of p53 and apoptosis by delta 12-PGJ2 in human hepatocarcinoma SK-HEP-1 cells.
FEBS Lett
368:
348-52,
1995[ISI][Medline].
27.
Lehmann, JM,
Moore LB,
Smith-Oliver TA,
Wilkison WO,
Willson TM,
and
Kliewer SA.
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor
(PPAR
).
J Biol Chem
270:
12953-12956,
1995[Abstract/Free Full Text].
28.
Mahmud, I,
Smith DL,
Whyte MA,
Nelson JT,
Cho D,
Tokes LG,
Alvarez R,
and
Wills AL.
On the identification and biological properties of prostaglandin J2.
Prostaglandins Leukot Med
16:
131-146,
1984[ISI][Medline].
29.
Mosmann, T.
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J Immunol Methods
65:
55-63,
1983[ISI][Medline].
30.
Needleman, P,
Turk J,
Jakschik BA,
Morrison AR,
and
Lefkowith JB.
Arachidonic acid metabolism.
Annu Rev Biochem
55:
69-102,
1986[ISI][Medline].
31.
Negishi, M,
Koizumi T,
and
Ichikawa A.
Biological actions of delta 12-prostaglandin J2.
J Lipid Mediat Cell Signal
12:
443-448,
1995[ISI][Medline].
32.
Negishi, M,
Sugimoto Y,
and
Ichikawa A.
Prostanoid receptors and their biological actions.
Prog Lipid Res
32:
417-434,
1993[ISI][Medline].
33.
Newton, R,
Kuitert LM,
Bergmann M,
Adcock IM,
and
Barnes PJ.
Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta.
Biochem Biophys Res Commun
237:
28-32,
1997[ISI][Medline].
34.
Nikola, TE.
Silent thyroiditis and subacute thyroiditis.
In: The Thyroid, edited by Braverman LE,
and Utiger RD.. Philadelphia, PA: Lippincott, 1991, p. 710-727.
35.
Odani, N,
Negishi M,
Takahashi S,
Kitano Y,
Kozutsumi Y,
and
Ichikawa A.
Regulation of BiP gene expression by cyclopentenone prostaglandins through unfolded protein response element.
J Biol Chem
271:
16609-16613,
1996[Abstract/Free Full Text].
36.
Offenbacher, S,
Odle BM,
and
Van Dyke TE.
The use of crevicular fluid prostaglandin E2 levels as a predictor of periodontal attachment loss.
J Periodontal Res
21:
101-112,
1986[ISI][Medline].
37.
Ohno, K,
Fukushima M,
Fujiwara M,
and
Narumiya S.
Induction of 68,000-dalton heat shock proteins by cyclopentenone prostaglandins. Its association with prostaglandin-induced G1 block in cell cycle progression.
J Biol Chem
263:
19764-19770,
1988[Abstract/Free Full Text].
38.
Ohno, K,
and
Hirata M.
Induction of gamma-glutamylcysteine synthetase by prostaglandin A2 in L-1210 cells.
Biochem Biophys Res Commun
168:
551-557,
1990[ISI][Medline].
39.
Park, KS,
Ciaraldi TP,
Abrams-Carter L,
Mudaliar S,
Nikoulina SE,
and
Henry RR.
PPAR-
gene expression is elevated in skeletal muscle of obese and type II diabetic subjects.
Diabetes
46:
1230-1238,
1997[Abstract].
40.
Ricote, M,
Li AC,
Willson TM,
Kelly CJ,
and
Glass CK.
The peroxisome proliferator-activated receptor-
is a negative regulator of macrophage activation.
Nature
391:
79-82,
1998[ISI][Medline].
41.
Roger, PP,
and
Dumondt JE.
Factors controlling proliferation and differentiation of canine thyroid cells cultured in reduced serum conditions: effects of thyrotropin, cyclic AMP and growth factors.
Mol Cell Endocrinol
36:
79-93,
1984[ISI][Medline].
42.
Rossi, A,
Kapahi P,
Natoli G,
Takahashi T,
Chen Y,
Karin M,
and
Santoro MG.
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I
B kinase.
Nature
403:
103-108,
2000[ISI][Medline].
43.
Santisteban, P,
Kohn LD,
and
Di Lauro R.
Thyroglobulin gene expression is regulated by insulin and insulin-like growth factor I, as well as thyrotropin, in FRTL-5 thyroid cells.
J Biol Chem
262:
4048-4052,
1987[Abstract/Free Full Text].
44.
Santoro, MG,
Garaci E,
and
Amici C.
Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells.
Proc Natl Acad Sci USA
86:
8407-8411,
1989[Abstract].
45.
Satoh, T,
Furuta K,
Suzuki M,
and
Watanabe Y.
Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells.
Biochem Biophys Res Commun
258:
50-53,
1999[ISI][Medline].
46.
Schoonjans, K,
Martin G,
Staels B,
and
Auwerx J.
Peroxisome proliferator-activated receptors, orphans with ligands and functions.
Curr Opin Lipidol
8:
1591-1566,
1997.
47.
Schoonjans, K,
Staels B,
and
Auwerx J.
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.
J Lipid Res
37:
907-925,
1996[Abstract].
48.
Spiegelman, BM.
PPAR-
: adipogenic regulator and thiazolidinedione receptor.
Diabetes
47:
507-514,
1998[Abstract].
49.
Staels, B,
Koenig W,
Habib A,
Merval R,
Lebret M,
Torra IP,
Delerive P,
Fadel A,
Chinetti G,
Fruchart JC,
Najib J,
Maclouf J,
and
Tedgui A.
Activation of human aortic smooth-muscle cells is inhibited by PPAR
but not by PPAR
activators.
Nature
393:
790-793,
1998[ISI][Medline].
50.
Tahara, K,
Grollman EF,
Saji M,
and
Kohn LD.
Regulation of prostaglandin synthesis by thyrotropin, insulin or insulin-like growth factor-I, and serum in FRTL-5 rat thyroid cells.
J Biol Chem
266:
440-448,
1991[Abstract/Free Full Text].
51.
Tasaki, Y,
Takamori R,
and
Koshihara Y.
Prostaglandin D2 metabolite stimulates collagen synthesis by human osteoblasts during calcification.
Prostaglandins
41:
303-313,
1991[Medline].
52.
Terry, CM,
Clikeman JA,
Hoidal JR,
and
Callahan KS.
Effect of tumor necrosis factor-alpha and interleukin-1 alpha on heme oxygenase-1 expression in human endothelial cells.
Am J Physiol Heart Circ Physiol
274:
H883-H891,
1998[Abstract/Free Full Text].
53.
Weetman, AP.
Thyroid autoimmune disease.
In: The Thyroid, edited by Braverman LE,
and Utiger RD.. Philadelphia, PA: Lippincott, 1991, p. 1295-1310.
54.
Yamashita, S,
Kimura H,
Ashizawa K,
Nagayama Y,
Hirayu H,
Izumi M,
and
Nagataki S.
Interleukin-1 inhibits thyrotrophin-induced human thyroglobulin gene expression.
J Endocrinol
122:
177-183,
1989[Abstract].
Am J Physiol Cell Physiol 279(6):C1859-C1869
0363-6143/00 $5.00
Copyright © 2000 the American Physiological Society